Logo image of IOVA

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Fundamental Analysis

NASDAQ:IOVA - US4622601007 - Common Stock

2.54 USD
+0.01 (+0.4%)
Last: 8/21/2025, 8:19:36 PM
2.55 USD
+0.01 (+0.39%)
Pre-Market: 8/22/2025, 8:29:02 AM
Fundamental Rating

3

Overall IOVA gets a fundamental rating of 3 out of 10. We evaluated IOVA against 549 industry peers in the Biotechnology industry. While IOVA seems to be doing ok healthwise, there are quite some concerns on its profitability. IOVA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IOVA has reported negative net income.
In the past year IOVA has reported a negative cash flow from operations.
In the past 5 years IOVA always reported negative net income.
IOVA had a negative operating cash flow in each of the past 5 years.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -38.83%, IOVA is in line with its industry, outperforming 58.65% of the companies in the same industry.
The Return On Equity of IOVA (-48.88%) is better than 65.94% of its industry peers.
Industry RankSector Rank
ROA -38.83%
ROE -48.88%
ROIC N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IOVA has a better Gross Margin (21.72%) than 73.04% of its industry peers.
The Profit Margin and Operating Margin are not available for IOVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IOVA has been increased compared to 1 year ago.
IOVA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IOVA has been reduced compared to a year ago.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.69, we must say that IOVA is in the distress zone and has some risk of bankruptcy.
IOVA's Altman-Z score of -1.69 is in line compared to the rest of the industry. IOVA outperforms 55.74% of its industry peers.
There is no outstanding debt for IOVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.69
ROIC/WACCN/A
WACC9.78%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

IOVA has a Current Ratio of 4.18. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.18, IOVA is in line with its industry, outperforming 47.18% of the companies in the same industry.
IOVA has a Quick Ratio of 3.64. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.64, IOVA perfoms like the industry average, outperforming 44.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.18
Quick Ratio 3.64
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.35% over the past year.
Looking at the last year, IOVA shows a very strong growth in Revenue. The Revenue has grown by 13698.99%.
EPS 1Y (TTM)26.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
Revenue 1Y (TTM)13698.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.73%

3.2 Future

Based on estimates for the next years, IOVA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.94% on average per year.
The Revenue is expected to grow by 45.14% on average over the next years. This is a very strong growth
EPS Next Y11.13%
EPS Next 2Y18.79%
EPS Next 3Y22.35%
EPS Next 5Y19.94%
Revenue Next Year84.47%
Revenue Next 2Y76.64%
Revenue Next 3Y63.64%
Revenue Next 5Y45.14%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOVA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IOVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as IOVA's earnings are expected to grow with 22.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.79%
EPS Next 3Y22.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IOVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (8/21/2025, 8:19:36 PM)

Premarket: 2.55 +0.01 (+0.39%)

2.54

+0.01 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners69.56%
Inst Owner Change-8.73%
Ins Owners0.37%
Ins Owner Change20.74%
Market Cap848.18M
Analysts75.56
Price Target10.2 (301.57%)
Short Float %22.91%
Short Ratio3.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.44%
Min EPS beat(2)-47.45%
Max EPS beat(2)4.58%
EPS beat(4)3
Avg EPS beat(4)-7.24%
Min EPS beat(4)-47.45%
Max EPS beat(4)8.26%
EPS beat(8)6
Avg EPS beat(8)1.78%
EPS beat(12)9
Avg EPS beat(12)4.27%
EPS beat(16)10
Avg EPS beat(16)2.98%
Revenue beat(2)0
Avg Revenue beat(2)-20.51%
Min Revenue beat(2)-40.82%
Max Revenue beat(2)-0.2%
Revenue beat(4)2
Avg Revenue beat(4)-2.57%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)24.03%
Revenue beat(8)2
Avg Revenue beat(8)-40.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.54%
PT rev (3m)-47.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.99
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.76
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.64
BVpS2.3
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.83%
ROE -48.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.72%
FCFM N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.86%
Cap/Sales 6.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.18
Quick Ratio 3.64
Altman-Z -1.69
F-Score5
WACC9.78%
ROIC/WACCN/A
Cap/Depr(3y)104.04%
Cap/Depr(5y)1124.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
EPS Next Y11.13%
EPS Next 2Y18.79%
EPS Next 3Y22.35%
EPS Next 5Y19.94%
Revenue 1Y (TTM)13698.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.73%
Revenue Next Year84.47%
Revenue Next 2Y76.64%
Revenue Next 3Y63.64%
Revenue Next 5Y45.14%
EBIT growth 1Y16.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.84%
EBIT Next 3Y15.56%
EBIT Next 5YN/A
FCF growth 1Y-4.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.9%
OCF growth 3YN/A
OCF growth 5YN/A